Regencell Bioscience Holdings (RGC) Payables (2021 - 2025)

Regencell Bioscience Holdings has reported Payables for 5 years, with the latest figure at $106.0 in Q4 2025.

• For the quarter ending Q4 2025, Payables changed N/A year-over-year to $106.0; the trailing twelve-month figure through Dec 2025 stood at $106.0 (changed N/A YoY), and the FY2025 full-year result was $2539.0, down 69.93% from the prior year.
• Payables for Q4 2025 stood at $106.0, down from $2539.0 in the prior quarter.
• The five-year high for Payables was $3.3 million in Q2 2021, with the low at $106.0 in Q4 2025.
• Historically, Payables has averaged $564295.0 across 5 years, with a median of $9506.5 in 2023.
• Annual changes were most pronounced in 2022 — Payables sank 99.06% — and 2024, when it fell 20.12%.
• Regencell Bioscience Holdings' Payables stood at $3.3 million in 2021, then slumped by 99.06% to $31300.0 in 2022, then slumped by 66.23% to $10570.0 in 2023, then slipped by 20.12% to $8443.0 in 2024, then plunged by 98.74% to $106.0 in 2025.
• The last three Payables figures came in at $106.0 (Q4 2025), $2539.0 (Q2 2025), and $8443.0 (Q2 2024), per Business Quant data.